z-logo
open-access-imgOpen Access
Correlation of In Vitro Fluconazole Susceptibility with Clinical Outcome for Severely Ill Patients with Oropharyngeal Candidiasis
Author(s) -
Sevtap Arıkan,
Murat Akova,
Murat Hayran,
Oktay Özdemir,
Mustafa Erman,
Deniz Gür,
Serhat Ünal
Publication year - 1998
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/513927
Subject(s) - fluconazole , candida glabrata , candida krusei , candida tropicalis , medicine , microbiology and biotechnology , neutropenia , candida albicans , univariate analysis , fungemia , mycosis , biology , immunology , antifungal , multivariate analysis , chemotherapy
We investigated the correlation between in vitro susceptibility to fluconazole and clinical response in severely ill patients with oropharyngeal candidiasis treated with fluconazole. The study included 48 adult patients, of whom 23 were neutropenic (absolute neutrophil count, < 500/mm3). Forty-eight isolates (20 Candida albicans, 12 Candida krusei, 10 Candida kefyr, 3 Torulopsis glabrata, and 3 Candida tropicalis) were tested for susceptibility to fluconazole with use of the macrodilution method of the National Committee for Clinical Laboratory Standards. A strain was considered to be susceptible to fluconazole if the MIC was < or = 8 micrograms/mL and resistant if the value was > or = 64 micrograms/mL. All but one of the resistant strains were C. krusei isolates. Species of causative Candida, persistent neutropenia, and susceptibility to fluconazole were significant predictors of clinical response by univariate analysis. Logistic regression analysis indicated that the only significant factor was the species of Candida isolates, validating the recently recommended MIC breakpoint and the correlation between clinical outcome and in vitro antifungal susceptibility.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom